Skin Barrier Function in Healthy Subjects and Patients with Atopic Dermatitis in Relation to Filaggrin Loss-of-Function Mutations  by Jakasa, Ivone et al.
Skin Barrier Function in Healthy Subjects and Patients with
Atopic Dermatitis in Relation to Filaggrin Loss-of-Function
Mutations
Journal of Investigative Dermatology (2011) 131, 540–542; doi:10.1038/jid.2010.307; published online 21 October 2010
TO THE EDITOR
Patients with atopic dermatitis (AD)
have a defective skin barrier that even
exists in nonlesional skin and is char-
acterized by increased transepidermal
water loss (TEWL) as well as enhanced
percutaneous penetration of both lipo-
philic and hydrophilic compounds
(Hata et al., 2002; Jakasa et al., 2006,
2007; Gupta et al., 2008; Proksch et al.,
2008; Jensen et al., 2009). Various
causes for the impaired barrier in AD
have been suggested, including an
aberrant composition and structure of
the intercellular lipid bilayers and an
altered expression of the cornified
envelope and keratinocyte structural
proteins (Proksch et al., 2008). Further-
more, barrier function in nonaffected
skin has been shown to be dependent
on disease activity (Chamlin et al.,
2002; Jakasa et al., 2006; Gupta et al.,
2008). The well-established association
between filaggrin gene (FLG) loss-of-
function mutations and AD supports the
hypothesis that an intrinsically impaired
skin barrier may be a primary step in
the development of AD (Brown and
McLean, 2009; O’Regan et al., 2009).
This seems plausible because filaggrin
is a key epidermal protein that regulates
several functions critical for the struc-
ture and composition of the stratum
corneum (SC) (Kezic et al., 2008;
Brown and McLean, 2009; O’Regan
et al., 2009). Previous investigators
have reported contrasting findings re-
garding the influence of FLG mutations
on the skin barrier in AD (Hubiche
et al., 2007; Nemoto-Hasebe et al.,
2009; Jungersted et al., 2010). Further-
more, because only one-third of AD
patients have FLG loss-of-function mu-
tations, these mutations only explain
the barrier abnormalities in a subset of
AD patients. Therefore, the main objec-
tive of this study was to investigate
whether the barrier reduction of nonle-
sional skin on AD patients was limited
to carriers of FLG mutations.
This study was based on our pre-
vious investigations that reported an
impaired skin barrier for polyethylene
glycols (PEG) of different molecular
weights and sodium lauryl sulfate
(Jakasa et al., 2006, 2007). In this
investigation, we genotyped the sub-
jects who participated in the previous
studies. To obtain a sufficient sample
size for the groups, we recruited more
subjects from the outpatient clinic of
the Academic Medical Centre and
through a public advertisement. After
recruitment, our study population con-
sisted of 20 healthy individuals who
were wild type for FLG mutations
(CTRL-wt), 15 AD patients who were
wild type for FLG (AD-wt), and 17 AD
patients who were heterozygous for
FLG (AD-Flg). All subjects were of
Dutch Caucasian decent. The charac-
teristics of all subjects are presented in
Table 1. The medical ethics committee
of the Academic Medical Center,
University of Amsterdam, approved
the experimental protocol. All subjects
gave their written, informed consent.
The study was conducted according
to the Declaration of Helsinki
Principles.
The skin barrier in the nonlesional
skin was assessed by TEWL and by
percutaneous penetration of PEG (PEG
370). The penetration of PEG 370 was
characterized by the diffusivity (D),
diffusion rate constant (D/L2), and
partition of PEG 370 into the SC (Ksc/v).
For a detailed method description,
please refer to our previous study
(Jakasa et al., 2007). Genotype analysis
was performed for the four most pre-
valent mutations in European Cauca-
sians: R501X, 2282del4, R2447X, and
S3247X, according to the procedure
described elsewhere (Sandilands et al.,
2007).
The results of this study showed
that AD patients, irrespective of their
FLG genotype, have an altered skin
barrier. As seen in Figure 1a, a signi-
ficant difference in TEWL was found
between CTRL-wt and AD patients
with or without FLG mutations. Similar
results were also obtained for the
percutaneous penetration of PEG 370.
Compared with CTRL-wt, both AD
patient subgroups had a higher
apparent diffusion coefficient D and
diffusion rate (D/L2) of PEG 370
(Figure 1b and c). Increased diffusivity
of PEG 370 resulted in a higher perme-
ability coefficient (Kp) of PEG 370 in
AD-Flg patients (Figure 1e). However,
in AD-wt patients, the higher diffusivity
of PEG was offset by a decrease in
the partition coefficient of PEG 370
(Figure 1d). Lower partition of PEG in
AD patients had previously been re-
ported (Jakasa et al., 2007); neverthe-
less, this study showed that this effect
was limited to only AD-wt patients. A
reduction in the partition of PEG 370
suggests an altered composition
and/or structure of the SC in AD-wt
patients; however, the reason for this is
not clear.
In most studies related to AD, skin
barrier function was assessed by mea-
suring TEWL. It is still unclear whether
TEWL is also a good parameter of the
skin barrier for the ingress of com-
pounds (Proksch et al., 2008; Jensen
et al., 2009). Scharschmidt et al. (2009)
reported increased penetration of a
water-soluble compound in filaggrin-
deficient flaky tail (ft/ft) mice when
compared with wt/wt mice, however
basal TEWL values in ft/ft mice were in
Abbreviations: AD, atopic dermatitis; FLG, filaggrin; PEG, polyethylene glycol; SC, stratum corneum;
TEWL, transepidermal water loss
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the range of normal values. The en-
hanced TEWL and increased diffusivity
of PEG 370 observed in the present
study suggests impairment of the skin
barrier in both directions. This was
further supported by a positive correla-
tion between TEWL and D/L2 (r¼0.34;
P¼0.006).
In summary, this study demonstrated
a reduced skin barrier in AD patients,
irrespective of FLG genotype, implying
that other factors besides FLG loss-of-
function mutations modulate skin bar-
rier integrity. Enhanced TEWL and
diffusivity in AD suggests defects in
the intercellular lipid bilayers of the SC.
The mechanisms underlying the
disturbance of lipid organization in the
SC might be different in AD patients
with and without FLG mutations.
Therefore, an investigation that exam-
ined the composition and the organiza-
tion of intercellular lipids of the
SC in AD patients in relation to FLG
genotype and state of disease would be
interesting.
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Figure 1. Skin barrier parameters in healthy subjects and AD patients. (a) Transepidermal water loss (TEWL), (b) diffusion coefficient (D), (c) diffusion rate
constant (D/L2), (d) SC/vehicle partition coefficient (Ksc/v), and (e) permeability coefficient (Kp). AD-Flg, AD patients with FLGmutations; AD-wt, AD patients without
FLG mutations; CTRL-wt, control subjects without FLG mutations. The results are shown as mean values±SD (a) or as median with interquartile range (b-e).
Analysis of variance (ANOVA) followed by a post hoc Bonferroni’s multiple comparison test was used to compare means between the two AD groups and controls.
For other parameters (b-e), we applied a nonparametric Kruskal–Wallis test followed by Dunn’s post hoc multiple comparison tests. *Po0.05, **Po0.01.
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The Dermoscopical and Histopathological Patterns of
Nevi Correlate with the Frequency of BRAF Mutations
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TO THE EDITOR
The frequency of BRAF mutations among
nevi is variable (Thomas, 2006), but little
is known about the frequency among
nevi, stratified by dermoscopy and by the
detection method.
In this study, we evaluated BRAF
status in 45 nevi from 43 patients
(23 women, mean age 39.9 years) using
the Sanger method (Loewe et al., 2004);
a random subset of 24 of these nevi was
tested by the more sensitive ultradeep
pyrosequencing (UDPS, Huse et al.,
2007; Tan et al., 2008; See Supplemen-
tary Data: Material and Methods S1,
Supplementary Tables S1 and S2 online).
RESULTS
Patient demographics, anatomic loca-
tion of nevi, dermoscopic patterns,
histopathological diagnosis, and results
of the genetic tests using Sanger
and UDPS are summarized in Table 1.
Dermoscopically, the 45 nevi consisted
of 17 (37.7%) reticular nevi (R), 5
(11.1%) globular nevi (G), 12 (26.6%)
mixed reticular nevi with central glo-
bules/homogeneous areas (MC), and 11
(24.4%) mixed reticular/homogeneous
nevi with peripheral globules (MP).
Using Sanger method, 6 of the 45
nevi (13.3%) contained BRAFV600E;
their dermoscopic patterns were G
(n¼2), MC (n¼ 2), and MP (n¼ 2),
and all (n¼6) were compound nevi on
histopathology. None of the nevi clas-
sified as R on dermoscopy or as jun-
ctional nevi on histopathology showed
BRAF mutations. Patients with nevi
harboring BRAFV600E were younger
than those with wild-type BRAF (30
versus 41 years, respectively; P¼0.03).
Using UDPS, 19 (79.2%) of the
24 randomly selected nevi were
BRAFV600E positive, including G nevi
(100%), MP nevi (90.9%), R nevi (75%),
and MC nevi (57%). Six nevi showed
heterogeneity of mutations (patients 3, 9,
14 and 16–18) and two nevi (patients 1
and 3), which were negative for
BRAFV600E, revealed p.K601E variant.
Representative electropherogramms are
depicted in Figure 1 (lanes 3 and 4).
There was no significant age difference
between patients with BRAFV600E nevi
and patient whose nevi showed wild-
type BRAF (37 versus 44 years, respec-
tively; P¼ 0.20).
COMMENT
The frequency of BRAF mutations
among nevi was highly dependent on
the sensitivity of the employed method;
only 13.3% of nevi showed BRAF
mutation using Sanger method,
whereas 79.2% showed mutation with
UDPS. The finding of BRAF mutation
by UDPS and not by Sanger method
probably attests to clonal heterogeneity
within the nevus, whereby clones of
BRAF mutations and clones with wild-
type BRAF coexist (Lin et al., 2009). The
age difference seen between patients
Abbreviations: G, globular nevi; MC, mixed reticular nevi with central globules/homogeneous areas;
MP, mixed reticular/homogeneous nevi with peripheral globules; R, reticular nevi; UDPS, ultradeep
pyrosequencing
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